Response to Article “Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?”

Novaria Sari Dewi Panjaitan, Christina Safira Whinie Lestari, Masri Sembiring Maha

Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Cibinong, West Java, Indonesia

Correspondence: Novaria Sari Dewi Panjaitan, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Jl. Raya Bogor No. 490, Km. 46, Cibinong, West Java, Indonesia, Email nova014@brin.go.id

Dear editor

Diabetes mellitus is one of metabolic diseases characterized by the elevated blood glucose levels. There are growing studies regarding the effect of diabetes to the development of other diseases such as hypertension, stroke, and even blindness. In the study performed by Dzięgielewska-Gęsiak et al, the comparison of two different treatments in diabetic type-2 patients regarding the effect to the microbiota composition was shown and discussed. Their study compared the microbiota profile in patients treated by metformin only and metformin supplemented with insulin. This study is an interesting and informative study, which gives a novel idea and hint of the different pattern of microbiota composition as the effect of different treatments given to patients. However, certain suggestions are given to the authors as consideration for their future studies.

The alteration of homeostatic gut microbiota composition has been continuously reported to play important role in the health field, especially in metabolic diseases, such as diabetes mellitus. The study performed by Dzięgielewska-Gęsiak, et al, compared the profile of gut microbiota of the patients with diabetes mellitus type-2 given by two different treatments, metformin or metformin and insulin. Their results showed that there were no significant differences in the gut microbiota profile detected and analyzed from the patients treated with metformin compared to those treated with metformin and insulin. A question addressed here was why and how? Were the patients included in this study maintaining significant diet and life circumstances for that long time? Does insulin as a hormonal agent really do nothing in the gut microbiota alteration? Meanwhile, the microbiota composition was reported as one of the essential aspects in the development of metabolic diseases and one of factors causing the metabolic disorders itself, in which diabetes mellitus is included.

After a deep reading, we provided several suggestions for the authors of this study or even for other scientists in the field as worth considering suggestions for being hopefully unexplored in the future studies. The long term treatment with metformin only or metformin+insulin, based on this particular study, caused no significant effect on the gut microbiota profile of the patients whom got the treatment for more than five years. However, there could be significant differences in gut microbiota profile if being compared to patients whom were just recently being treated with metformin. The comparison of gut microbiota profile could have been performed in comparing those in patients treated with metformin and other different anti-diabetic agent (treatment).

The abundant bacteria found in the undertreatment type-2 diabetic patients were Clostridiales, Firmicutes and Verrucomicrobia. Meanwhile, Bacteroidetes and Proteobacteria were in the smaller total proportions. In previous study, Bacteroidetes was reported to be associated with the high risk of diabetes mellitus while being compared to the
microbiota composition of healthy individuals.\textsuperscript{4} The profile of \textit{Bacteroidetes} in both groups of patients treated by metformin or metformin+insulin was low in this study, probably due to the effect of the anti-diabetic drug. Anyways, the role of insulin addition under metformin in altering the gut microbiota composition to the healthy composition for type-2 diabetes mellitus cases was not completely unraveled in this study. Therefore, these aspects could be revealed in the future studies.

**Acknowledgments**

Full acknowledgements are conveyed to all supports given to all authors of the study commented in this letter during the study period. The authors also would like to appreciate Dr. Sunarno, the Head of Center for Biomedical Research in National Research and Innovation Agency (BRIN) for his continuous support during the letter manuscript preparation.

**Author Contributions**

NSDP went through the cited publications and analyzed the reported data. NSDP designed and conceived the critical design of the letter. NSDP wrote the original letter draft. CSWL and MSM recommended required corrections. NSDP, CSWL and MSM did necessary revision for improvement of the manuscript accordingly.

**Disclosure**

The authors report no conflicts of interest in this communication.

**References**


Dove Medical Press encourages responsible, free and frank academic debate. The content of the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content and accuracy of any letter to the editor.